Cassava Sciences to Present at the Jefferies Global Healthcare Conference
01. Juni 2023 09:15 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, June 01, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that its management has...
Cassava Sciences Completes Patient Dosing in a Randomized Controlled Trial of Simufilam in Alzheimer’s Disease
11. Mai 2023 09:15 ET
|
Cassava Sciences, Inc.
The Cognition Maintenance Study (CMS) is a 6-month, Randomized Controlled Trial of Simufilam in Over 125 Patients with Alzheimer’s Disease.Primary Outcome Measures Are Safety and Change in Cognition...
New Data by Academic Researchers Highlights Biological Activity of Simufilam on Filamin A
08. Mai 2023 09:15 ET
|
Cassava Sciences, Inc.
New in vitro data from Europe show that simufilam can reverse altered filamin A protein (FLNA) in pituitary tumor cells, leading to improved cell signaling.Data suggest FLNA is a central factor...
Cassava Sciences Reports Q1 2023 Financial Results and Operating Updates
01. Mai 2023 09:00 ET
|
Cassava Sciences, Inc.
Over 1,244 Alzheimer’s patients now enrolled in Phase 3 studies of simufilam.Completion of patient enrollment for Phase 3 program still expected Q4 2023.$187.5 Million Cash and Cash Equivalents at...
Cassava Sciences to Present at the 2023 H.C. Wainwright Investor Conference
26. April 2023 09:12 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, April 26, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that Remi Barbier,...
Cassava Sciences Reports Full-year 2022 Financial Results and Operating Updates
28. Februar 2023 09:15 ET
|
Cassava Sciences, Inc.
In Q2 2023, We Expect to Complete Patient Dosing for our Cognition Maintenance Study in Alzheimer’s disease.In Q3 2023, We Expect to Announce Results of our Cognition Maintenance Study.In Q4 2023, We...
Cassava Sciences Announces Patient Enrollment Update for Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s Disease
08. Februar 2023 09:15 ET
|
Cassava Sciences, Inc.
953 Alzheimer’s Patients Are Now Enrolled Across Phase 3 Studies Both Phase 3 Studies Have Passed the Halfway Mark for Enrollment Goal Is to Complete Enrollment for Both Phase 3 Studies by Year-End...
Cassava Sciences Announces Positive Top-Line Clinical Results in Phase 2 Study Evaluating Simufilam in Alzheimer’s Disease
24. Januar 2023 09:15 ET
|
Cassava Sciences, Inc.
ADAS-Cog mean scores changed minimally over 1 year in patients with mild-to-moderate Alzheimer’s disease treated with open-label simufilam tablets.47% of patients improved on ADAS-Cog over 1 year, and...
Cassava Sciences Mourns the Death of Board Member and Officer Nadav Friedmann, PhD, MD
20. Dezember 2022 09:15 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) announced today that a valued and long-time member of the Company, Nadav Friedmann, PhD, MD, has died following...
Cassava Sciences Announces Completion of Dosing in Open-label Study of Simufilam for Alzheimer’s Disease
06. Dezember 2022 09:15 ET
|
Cassava Sciences, Inc.
Outside Biostatisticians with Specific Expertise in Alzheimer’s Disease Will Conduct an Independent Statistical Analysis on The Clinical Dataset. Clinical Dataset May Be Announced Approximately...